Evoke Pharma (NASDAQ:EVOK – Get Free Report) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.24), Zacks reports. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.
Evoke Pharma Stock Up 4.6 %
NASDAQ:EVOK traded up $0.17 during trading hours on Thursday, reaching $3.85. 13,249 shares of the stock were exchanged, compared to its average volume of 10,855. Evoke Pharma has a twelve month low of $3.44 and a twelve month high of $12.32. The business has a 50-day moving average of $4.56 and a two-hundred day moving average of $4.72. The company has a market capitalization of $5.72 million, a price-to-earnings ratio of -0.35 and a beta of 0.12.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Evoke Pharma in a research note on Wednesday. They issued a “sell” rating on the stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Pros And Cons Of Monthly Dividend Stocks
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What Are the U.K. Market Holidays? How to Invest and Trade
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
